FDA Medical Device Recall Classes: Class I, II & III Explained

When the FDA determines that a medical device is defective, mislabeled, or potentially harmful, it initiates a recall. But not all recalls carry the same weight. The FDA classifies every recall into one of three classes — Class I, Class II, or Class III — based on how likely the defect is to cause harm and how severe that harm could be. Understanding these classifications is essential for manufacturers, regulatory affairs professionals, healthcare providers, and distributors who must respond correctly and within the right timeframe.

This guide explains exactly what each recall class means, how the classification process works, what obligations it triggers, and how to track recalls systematically.

What Is a Medical Device Recall?

A medical device recall is an action taken to address a product that violates FDA regulations or that could present a risk to health. Despite the name, a "recall" does not always mean the device is physically removed from the market. Recalls can include:

• Product removals: Physical retrieval of devices from the distribution chain or end users
• Field corrections: Repairs, modifications, relabeling, or software updates performed in the field
• Safety notifications: Letters, alerts, or communications informing users of risks and recommended actions

Voluntary vs. Mandatory Recalls

The vast majority of FDA medical device recalls are voluntary — the manufacturer identifies a problem and initiates the recall on its own, then reports it to the FDA under 21 CFR Part 806. The FDA reviews, classifies, and monitors the recall but does not order it.

In rare cases, the FDA can issue a mandatory recall under Section 518(e) of the Federal Food, Drug, and Cosmetic Act. This authority is used when a manufacturer refuses to recall a device that presents a reasonable probability of serious adverse health consequences or death. Mandatory recalls are extremely uncommon — the FDA has exercised this authority only a handful of times in the agency's history.

There is also a third category: FDA-requested recalls, where the FDA identifies the problem and asks the manufacturer to initiate a voluntary recall. Most manufacturers comply, which is why mandatory orders remain rare.

Recall Classification: Class I, II, and III

Once a recall is reported to the FDA, the agency evaluates the health hazard and assigns a classification. This classification determines the urgency of the response and the scope of required actions.

Class I — Most Serious

Definition: There is a reasonable probability that use of, or exposure to, a violative product will cause serious adverse health consequences or death.

Class I is the most severe classification. These recalls involve defects that can directly harm or kill patients. The FDA expects immediate action: rapid customer notification, field corrections or removals, and close coordination with the agency.

Key characteristics:

• Highest urgency — response expected within hours to days
• Typically requires direct notification of all affected customers and end users
• FDA may issue a public safety alert via MedWatch
• Recall effectiveness checks are mandatory
• Often receives media coverage

Real-world examples:

Device	Manufacturer	Year	Issue
Implantable cardioverter-defibrillators (ICDs)	Medtronic	2005	Short circuit in Sprint Fidelis leads could cause failure to deliver therapy, resulting in sudden cardiac death. Over 268,000 leads affected.
Insulin pumps (MiniMed 600/700 series)	Medtronic	2019-2023	Multiple recalls for retainer ring defects that could cause over- or under-delivery of insulin, risking hypoglycemia or diabetic ketoacidosis.
Duodenoscopes (TJF-Q180V)	Olympus	2016	Elevator mechanism design made adequate reprocessing difficult, linked to superbug outbreaks (CRE infections) across multiple hospitals.
Power morcellators	Multiple	2014	Risk of spreading undiagnosed uterine cancer during laparoscopic surgery. FDA issued a safety communication discouraging use.
Philips CPAP/BiPAP machines	Philips Respironics	2021	Polyester-based polyurethane (PE-PUR) sound abatement foam degradation, with risk of inhalation or ingestion of particles and off-gassing of toxic chemicals. Over 5.5 million units recalled worldwide.

Class II — Moderate

Definition: Use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote.

Class II recalls are the most common category, representing roughly 60-70% of all FDA device recalls in a typical year. The defects are real but the risk profile is lower — harm is either temporary, reversible, or unlikely.

Key characteristics:

• Moderate urgency — response expected within days to weeks
• Customer notification usually required, though the scope may be narrower
• FDA may or may not issue a public safety communication
• Recall effectiveness checks are typically required
• Covers a wide range of issues from software bugs to labeling errors with clinical impact

Real-world examples:

Device	Manufacturer	Year	Issue
Blood glucose monitors	Abbott (FreeStyle)	2019	Test strips providing inaccurate readings in certain conditions, potentially leading to incorrect insulin dosing.
Patient monitors	GE Healthcare	2020	Software defect causing intermittent failure to display alarm notifications, potentially delaying clinical response.
Hip implant components	Stryker	2016	Labeling error where the packaging indicated incorrect component sizes, risking intraoperative complications.
Ventilator circuits	Various	2020-2021	Multiple recalls during COVID-19 for ventilator accessories with dimensional nonconformances that could cause leaks.
Surgical staplers	Ethicon (J&J)	2023	Malfunction reports where stapler failed to fire or fired incompletely, requiring conversion to open surgery.

Class III — Least Serious

Definition: Use of, or exposure to, a violative product is not likely to cause adverse health consequences.

Class III recalls involve violations that are unlikely to cause any harm. These are typically administrative, labeling, or documentation issues that technically violate FDA regulations but do not present a meaningful clinical risk.

Key characteristics:

• Lowest urgency — response measured in weeks
• Customer notification may not be required depending on the nature of the issue
• No public safety alert from FDA
• Recall effectiveness checks may be waived
• Often resolved through revised labeling, updated IFUs, or documentation corrections

Real-world examples:

Device	Issue Type	Description
Surgical gloves	Labeling	Missing or incorrect lot number on outer packaging
Wound dressings	Packaging	Inner sterile barrier intact but outer box missing required regulatory markings
Diagnostic reagent kits	Documentation	Instructions for Use (IFU) referenced an outdated software version
Examination tables	Labeling	Weight capacity label missing from one production run
Thermometers	Documentation	CE marking displayed but Declaration of Conformity referenced wrong standard

Comparison Table: Class I vs. Class II vs. Class III

Attribute	Class I	Class II	Class III
Health risk	Serious harm or death probable	Temporary/reversible harm, or remote probability of serious harm	Unlikely to cause harm
Urgency	Immediate	Days to weeks	Weeks
Customer notification	Required — all affected parties	Usually required	May not be required
FDA safety alert	Frequently issued	Sometimes issued	Rarely issued
Effectiveness checks	Mandatory	Typically required	May be waived
Typical frequency	~5-10% of annual recalls	~60-70% of annual recalls	~20-30% of annual recalls
Public attention	High	Moderate	Low
Examples	Defective pacemaker leads, contaminated implants	Software bugs in monitors, mislabeled implant sizes	Missing lot numbers, IFU typos

Recall Statistics: How Many Recalls Happen Each Year?

The FDA processes a substantial volume of recall activity every year. Based on data from FDA Enforcement Reports and the openFDA API:

Year	Class I	Class II	Class III	Total
2020	58	512	198	768
2021	71	635	223	929
2022	64	587	201	852
2023	70	611	189	870
2024	68	598	195	861
2025	72	621	207	900

Key trends to note:

• Class II recalls consistently represent the majority of all recall actions
• Class I recall volume has remained relatively stable, averaging 60-75 per year
• Software-related recalls have increased significantly since 2020, driven by the growing prevalence of Software as a Medical Device (SaMD) and connected devices
• COVID-19-era emergency use authorizations (EUAs) led to a spike in recalls during 2021-2022 as products authorized under relaxed standards were later found to have quality issues

Manufacturer Obligations When a Recall Is Issued

When a manufacturer identifies a defect that requires a recall, several regulatory obligations are triggered:

1. Reporting to FDA (21 CFR Part 806)

Manufacturers and importers must submit a written report to the FDA within 10 working days of initiating a correction or removal. This report must include:

• Device identity (brand name, model number, product codes)
• Description of the event and the health hazard evaluation
• Number of units manufactured, distributed, and in inventory
• Distribution information (dates, quantities, consignees)
• Proposed strategy for the correction or removal
• Whether a health hazard evaluation has been conducted

Exception: If the correction or removal is initiated by a device user facility (hospital, nursing home), the reporting obligation falls on the manufacturer, not the facility.

2. Health Hazard Evaluation

The manufacturer must conduct a formal health hazard evaluation considering:

• The disease or injuries that have occurred or could occur
• Assessment of hazard to various population groups (elderly, children, immunocompromised)
• Whether the defect could cause harm in foreseeable use and misuse scenarios
• The degree to which the defect is obvious to the user

The FDA uses this evaluation, along with its own assessment, to assign the recall classification.

3. Recall Strategy

The manufacturer must develop and execute a recall strategy that specifies:

• Depth of recall: To what level in the distribution chain the recall extends (wholesale, retail, consumer/user)
• Public notification: Whether press releases, public warnings, or direct mailings are needed
• Effectiveness checks: What percentage of consignees will be contacted to verify they received the recall notice and took appropriate action

4. Status Reports

Manufacturers must submit periodic status reports to the FDA until the recall is terminated. These reports include the number and percentage of consignees notified, the number of responses received, and the quantity of product returned or corrected.

5. Recall Termination

A recall is terminated when the FDA determines that all reasonable efforts have been made to correct or remove the product, and that the recall strategy has been effective. The manufacturer must request termination — recalls do not automatically expire.

How Recalls Are Tracked: Key FDA Systems

FDA Enforcement Reports

Published weekly (typically on Wednesdays), Enforcement Reports list all newly classified recall actions. Each entry includes the recall number, firm name, product description, classification, code information (lot/model numbers), distribution data, and quantity recalled. These reports are available in HTML, CSV, and XML formats.

recalls.fda.gov

The FDA's primary public recall database. Allows searching by keyword, date range, recall classification, and product type. Each record links to the full recall notice.

openFDA API

The /device/recall endpoint provides machine-readable access to recall data. Supports filtering by classification, date, product code, recalling firm, and distribution pattern. Note that openFDA data can lag behind recalls.fda.gov by several days to weeks.

MedWatch Safety Alerts

For high-profile recalls (especially Class I), the FDA publishes safety alerts via MedWatch. Healthcare professionals and consumers can subscribe to MedWatch email alerts for real-time notifications.

MAUDE (Manufacturer and User Facility Device Experience)

While MAUDE is an adverse event database rather than a recall database, it is a leading indicator. Clusters of similar adverse event reports for the same device model often precede a formal recall. Monitoring MAUDE proactively can provide early warning.

Impact on CE Marking and International Markets

A recall issued in one market frequently has implications in other jurisdictions. Medical device manufacturers operating internationally must consider:

EU MDR Requirements

Under EU MDR Article 87, manufacturers must report Field Safety Corrective Actions (FSCAs) to their Notified Body and the relevant competent authority. An FSCA includes any corrective action taken to reduce a risk of death or serious deterioration in health. If a device is recalled by the FDA, the manufacturer must evaluate whether the same defect affects CE-marked units and, if so, initiate an FSCA and issue a Field Safety Notice (FSN) to European customers.

EUDAMED

The European Database on Medical Devices (EUDAMED) will serve as the central repository for FSCA and FSN data across the EU. Manufacturers will be required to submit vigilance reports and FSCAs through EUDAMED, making cross-border recall tracking more transparent.

MDSAP Countries

Countries participating in the Medical Device Single Audit Program (MDSAP) — including the US, Canada, Australia, Japan, and Brazil — have varying recall notification requirements, but a recall in one MDSAP country typically triggers review in others. The Australian TGA, Health Canada, Japan's PMDA, and Brazil's ANVISA all maintain their own recall databases and notification requirements.

Practical Impact

• A Class I FDA recall for a device sold in 30 countries may require simultaneous notifications to 30 separate regulatory authorities
• Recall classification does not always align across jurisdictions — the FDA may classify a recall as Class II while the TGA classifies the same issue as a "hazard alert"
• Manufacturers must maintain distribution records by market to enable targeted recall execution

How to Set Up Real-Time Recall Monitoring

For organizations managing multiple device lines or monitoring competitors and suppliers, manual recall tracking across multiple FDA systems and international regulators is unsustainable. Here is what a robust monitoring workflow looks like:

Minimum Viable Monitoring (Manual)

1. Subscribe to MedWatch email alerts — covers FDA Safety Communications and high-profile recalls
2. Check FDA Enforcement Reports weekly — published every Wednesday, covers all classified recall actions
3. Set Google Alerts for key manufacturers, device names, and "FDA recall" keywords
4. Review recalls.fda.gov monthly for trends in your device category

Intermediate Monitoring (Semi-Automated)

1. Build openFDA API queries filtered by your product codes and device categories
2. Schedule weekly API pulls and compare results against your product portfolio
3. Monitor MAUDE for adverse event clusters that may precede recalls
4. Track international recalls by checking TGA, Health Canada, and MHRA databases periodically

Advanced Monitoring (Automated)

1. Deploy a regulatory intelligence platform that aggregates recall data from multiple sources — FDA, EU competent authorities, TGA, Health Canada, PMDA, and others — into a single feed
2. Configure product-specific filters so that only recalls relevant to your device portfolio, component suppliers, or competitive landscape are flagged
3. Set classification-based alert priorities — Class I recalls trigger immediate notifications; Class II recalls are delivered daily; Class III recalls are batched weekly
4. Integrate recall data with your QMS so that recall assessments feed directly into CAPA and post-market surveillance workflows

MedFlux provides this level of monitoring across 27 regulators worldwide. Recall data is aggregated, classified, and delivered to your team in real time — filtered by device category, manufacturer, and classification. Class I recalls are surfaced within hours of publication, not days.

Key Takeaways

1. Recall classification drives response urgency. Class I demands immediate action; Class III may require only documentation updates. Knowing the classification is the first step in any recall response.

2. Most recalls are voluntary. Manufacturers initiate the vast majority of recalls. FDA mandatory recalls are extremely rare.

3. The reporting clock starts immediately. Manufacturers have 10 working days from initiating a correction or removal to report to the FDA.

4. FDA data is fragmented. Recall information is spread across recalls.fda.gov, Enforcement Reports, MedWatch, MAUDE, and the openFDA API. No single source provides a complete, real-time picture.

5. International implications are real. An FDA recall for a globally distributed device triggers obligations in every market where the device is sold.

6. Proactive monitoring pays off. Organizations that track MAUDE reports and monitor recall trends by device category can identify emerging risks before they become formal recall actions.

---

MedFlux monitors FDA recalls, Enforcement Reports, MedWatch Safety Alerts, and 26 additional regulatory authorities in real time. Recall intelligence is filtered by your device portfolio, classified by urgency, and delivered the moment it matters. Stop checking five systems manually — let MedFlux surface what is relevant to your products, when it is relevant.